24 junio 2017

PharmaMar . La Biofarmacéutica va poco a poco consolidando su estructura alcista de medio plazo.

23/06/2017 - PHARMAMAR  .

 Pese haber encontrado resistencia sobre los 4.20 euros zonales, dicho nivel frenó el último alcista del valor, Pharmamar mantiene intacta su directriz alcista principal. De hecho, se encuentra bastante lejos de ella dado que esta transcurre a día de hoy sobre los 3.20 euros zonales. 

Cabe destacar que Pharmamar acumula una revalorización anual superior a los 40 puntos porcentuales por lo que toda corrección temporal debería ser interpretada como una sana regulación de osciladores.

La superación definitiva de los 4.35 euros zonales, cota correspondiente al triple máximo anual marcado durante los años 2010 y 2015, volvería a dejar al valor en fase de subida libre relativa, escenario proclive para desarrollar un segundo impulso estructural a gran escala.

 Los 4.80 euros zonales pasarían a ser su siguiente objetivo a reconquistar aunque no sería para nada descartable una prolongación adicional rumbo a los máximos marcados a mediados de 2008 entorno los 6 euros zonales. Por abajo, los 3.75 euros zonales correspondientes al último triple mínimo intradía, son por el momento la referencia de soporte a vigilar.

Soportes: 3.75, 3.60, 3.20, 3 euros
Resistencias: 4.20, 4.35, 4.50, 4.80, 5 euros
Objetivos: 4.35, 4.80, 5.20, 5.50, 6 euros zonales

Bayer Receives Positive CHMP Opinion for regorafenib for the Second-Line Systemic Treatment of Liver Cancer . Post by Celtia .

Resultado de imagen de regorafenib bayer*.- Positive opinion based on data from the Phase III RESORCE study, in which regorafenib demonstrated significant improvement in overall survival in hepatocellular carcinoma (HCC) patients previously treated with Nexavar® (sorafenib) .

*.- Approval could provide first treatment advance in nearly a decade .

*.- Final decision from the European Commission anticipated within the next two months .

BERLIN, Germany // June 23, 2017 .

 Bayer announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended regorafenib for the treatment of adult patients with hepatocellular carcinoma (HCC) who have been previously treated with Nexavar® (sorafenib). Regorafenib is the first and only treatment that has demonstrated a significant improvement in overall survival in second-line HCC patients who previously had no other options. The final decision of the European Commission on the marketing authorization is expected in the coming months. The anti-cancer medication from Bayer is already approved under the brand name Stivarga® in more than 90 countries worldwide for the treatment of metastatic colorectal cancer (CRC), including countries of the EU, and in more than 80 countries globally for the treatment of metastatic gastrointestinal stromal tumors (GIST), including countries of the EU. The product recently gained approval in the U.S. for second-line treatment of HCC and additional regulatory filings for Stivarga in HCC are under review in countries around the world, including China.

...